Sage Journals: Discover world-class research

Abstract

Sixty-two patients with multiple sclerosis (MS) were imaged monthly over a six-month (ie, seven monthly magnetic resonance images [MRI]) natural history period (NHP). Thereafter, patients were randomized to receive 11 or 33 μg of subcutaneously injected interferon beta 1a (IFNp-1 a) with imaging monthly for nine months and at months 12, 18 and 24 of therapy phase (TP). In the present exploratory post hoc analysis, the authors evaluated IFNβ-1a dose effect on reducing the size of contrast-enhancing lesions (CELs). MRIs performed at months 0, 3 and 6 of NHP and at months 3, 6, 9, 18 and 24 of TP were analysed. While a significant reduction in mean number of CELs was observed in both treatment groups of patients, the mean total volume and size of CELs was reduced only in patients undergoing therapy with 33 μg of IFNβ-1a. The latter suggests a significant dose effect exerted by IFNβ-1a in the evolution of CELs' dimensions during therapy. Multiple Sclerosis 2007; 13: 343-347. http://msj.sagepub.com

Keywords

contrast-enhancing lesions inflammation interferon beta lesion size magnetic resonance imaging multiple sclerosis

Get full access to this article

View all access options for this article.

References

McFarland HF , Frank JA , Albert PS , Smith ME , Martin R. , Harris JO et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis . Ann Neurol 1992; 32: 75866 .

Pozzilli C. , Bastianello S. , Koudriavtseva T. , Gasperini C. , Bozzao A. , Millefiorini E. et al. Magnetic resonance imaging changes with recombinant human interfleron-beta-1a: a short-term study in relapsing-remitting multiple sclerosis . J Neurol NeurosurgPsychiatry. 1996; 61: 251-58 .

The Prisms Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term eflficacy ofl interfleron-beta-1a in relapsing MS . Neurology 2001; 56: 1628-36 .

Schwid SR , Thorpe J. , Sharief M. , Sandberg-Wollheim M. , Rammohan K. , Wendt J. et al. Enhanced benefit ofl increasing interfleron beta-1a dose and flrequency in relapsing multiple sclerosis: the EVIDENCE Study . Arch Neurol 2005; 62: 785-92 .

van Waesberghe JH , van Walderveen MA , Castelijins JA , Scheltens P. , Lycklama a Nijeholt GJ et al. Patterns ofl lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfler MR . Am J Neuroradiol 1998; 19: 675-83 .

Ciccarelli O. , Giugni E. , Paolillo A. , Mainero C. , Gasperini C. , Bastianello S. et al. Magnetic resonance outcome ofl new enhancing lesion in patients with relapsing-remitting multiple sclerosis . Eur J Neurol 1999; 6: 455-59 .

Bruck W. , Bitsch A. , Kolenda H. , Bruck Y. , Stiefel M. , Lassmann H. Inflammatory central nervous system demyelination: correlation ofl magnetic resonance imaging findings with lesion pathology . Ann Neurol 1997; 42: 783-93 .

Bitsch A. , Kuhlmann T. , Stadelmann C. , Lassmann H. , Lucchinetti C. , Bruck W. A longitudinal MRI study ofl histopathologically defined hypointense multiple sclerosis lesions . Ann Neurol 2001; 49: 793-96 .

Hiehle JF , Grossman RI , Ramer KN , Gonzalez-Scarano F. , Cohen JA Magnetization transfler eflflects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images . AJNR Am J Neuroradiol 1995; 16: 69-77 .

10.

Miller DH , Altmann D. , Thompson AJ , Kappos L. , Wagner K. , Beckmann K. Sample size calculations flor a parallel groups, placebo-controlled treatment trial in secondary progressive multiple sclerosis using cerebral atrophy as the primary outcome measure . Neurology 2004 ; 62: A349 .

11.

Bagnato F. , Gupta S. , Ohayon JM , Stone RD , McFarland HF Sample size estimations flor MRI-monitored trials ofl MS considering reduction in flormation ofl new black holes as primary endpoint . Neurology 2005; 64: A243 .

12.

Filippi M. , Rovaris M. , Capra R. , Gasperini C. , Prandini F. , Martinelli V. et al. Interfleron beta treatment flor multiple sclerosis has a graduated eflflect on MRI enhancing lesions according to their size and pathology . J Neurol Neurosurg Psychiatry 1999; 67: 386-89 .

13.

Brex PA , Molyneux PD , Smiddy P. , Barkhof F. , Filippi M. , Yousry TA et al. The eflflect ofl IFNbeta-1b on the evolution ofl enhancing lesions in secondary progressive MS . Neurology 2001 ; 57: 2185-90 .

14.

Gupta S. , Solomon JM , Tasciyan TA , Cao MM , Stone RD , Ostuni JL et al. Interfleron-beta-1b eflflects on re-enhancing lesions in patients with multiple sclerosis . Mult Scler 2005; 11: 658-68 .

15.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-52 .

16.

Pellegrini P. , Totaro R. , Contasta I. , Berghella AM , Russo T. , Carolei A. et al. IFNβ-1a treatment and reestablishment ofl Th1 regulation in MS patients. Dose eflflects . Clin Neuropharmacol 2004; 27: 258-69 .

17.

Graber J. , Zhan M. , Ford D. , Kursch F. , Francis G. , Bever C. et al. Interfleron-β-1a induces increases in vascular cell adhesion molecule: implications flor its mode ofl action in multiple sclerosis . J Neuroimmunol 2005; 161: 169-76 .

18.

Paul WE Fundamental immunology, third edition. Raven Press .

An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis

Abstract

Keywords

Get full access to this article

References